The Insider Trade: Signal vs. Noise in Congressional and Corporate Filings

Before the names and tickers, a brief primer on the mechanics — because the disclosure system is designed to be technically transparent while remaining practically opaque.

Congressional filings (STOCK Act): Members of Congress and their spouses must report transactions between $1,001 and $15,000 as a range, not a precise number. Anything above $15,000 gets broken into higher range buckets. The result is that a senator can report a six-figure position as a vague range. Timeliness is also a persistent problem: the 45-day window means you are always trading information that is at least a month old. That said, patterns across multiple filings — particularly concentrated buys in a sector immediately following committee activity — remain meaningful.

Corporate Form 4 filings: These are faster (two business days) and more precise. The key variables: Is the insider buying on the open market, or is this an option exercise? Is it a new position or adding to an existing one? Is the purchase discretionary or part of a pre-arranged 10b5-1 plan? Open-market purchases with no pre-arranged plan, made by C-suite insiders or board members, are the most credible signal. Those are the ones we focus on.

The clustering effect: One insider buying is a data point. Three insiders at the same company buying in the same two-week window is a pattern worth examining. Congressional clustering — multiple members of the same committee buying the same sector — is the most underreported signal in public finance journalism.

Where to find the raw data: SEC EDGAR (Form 4), the House and Senate financial disclosure portals, and aggregation tools like OpenSecrets and the House Stock Watcher project all provide public access. We use these as our primary sources.

Defense spending is the sector most consistently correlated with congressional insider activity, and for structural reasons that have nothing to do with impropriety in any individual case. Members of the Armed Services Committees, the Appropriations defense subcommittees, and the Intelligence Committees are perpetually exposed to information about contract pipelines, procurement priorities, and budget line items that will not become public for months.

The durable mechanism here is the Pentagon's annual budget cycle and the continuing-resolution dance. When the defense budget is in flux — and it nearly always is — insiders with committee access know which programs are likely to survive, which contractors are positioned to absorb increases, and which platforms face the chopping block.

What to watch: Concentrated buying in defense primes (LMT, RTX, NOC, GD, BA defense segment) by members of Armed Services or Appropriations subcommittees, particularly in the window between classified briefings and public budget releases. Also watch the Tier 2 contractors — HII (shipbuilding), LDOS and SAIC (IT and intelligence services), CACI and MANT (professional services) — which often move on contract news before the primes do.

Signal vs. Noise this cycle: Broad-based selling in the defense sector by congressional members is more likely noise — estate planning, financial planner rebalancing, or index-fund adjustments that happen to include defense exposure. Concentrated buying in a single prime or a small cluster of Tier 2 contractors, in a period of active procurement discussion, is the signal worth tracking.

The institutional tell: When corporate insiders at a defense contractor cluster-buy within a short window, it often precedes a contract award that was known internally but not yet public. The Form 4 filing date relative to the contract announcement date is the variable to track.

No sector produces cleaner insider-trade signals than biopharma around FDA advisory committee meetings and drug approval decisions. The mechanism is direct: a company awaiting PDUFA date approval has a binary outcome that management almost certainly has a stronger read on than the market.

The pattern: Corporate insiders at clinical-stage and near-approval biotech companies often stop buying in the weeks immediately before a decision — not because they are selling, but because their legal compliance teams typically impose blackout windows ahead of material nonpublic events. An absence of insider selling in the pre-PDUFA window, combined with open-market buying in the three to six months preceding it, is a constructive signal.

Conversely, heavy insider selling at a biopharma company three to six months before an expected approval is worth noting — executives diversifying before a binary outcome is rational, but the scale and timing matter.

Congressional angle: Members of the Senate HELP Committee and the House Energy and Commerce Committee have oversight of FDA policy. Trades in pharma and biotech by these members warrant scrutiny, particularly around FDA user fee reauthorization cycles, drug pricing legislation windows, and biosimilar policy shifts — all of which affect sector multiples before they affect individual drugs.

Tickers to watch in this context: Large-cap pharma with major PDUFA or pipeline milestones (PFE, MRK, ABBV, LLY, BMY) are the congressional-disclosure names. For corporate insider signals, the more meaningful moves come from executives at mid-cap and small-cap biotechs with late-stage pipelines — companies where a single approval meaningfully affects enterprise value.

The noise: Insider selling by pharma executives under 10b5-1 plans established 12+ months earlier is not a signal about near-term prospects. It is a pre-planned diversification. Filter these out before drawing conclusions.

Federal infrastructure spending and energy policy create some of the most durable insider-trade patterns because the mechanism is slow-moving and highly visible to those inside the process. Unlike a drug approval (binary, fast) or a defense contract (complex, classified), infrastructure spending flows through publicly available grant announcements, loan programs, and regulatory approvals — but the order in which that money moves is often known to insiders well before public announcement.

The IRA and infrastructure money trail: The Inflation Reduction Act and the Infrastructure Investment and Jobs Act collectively represent hundreds of billions in directed federal spending. The implementing agencies — DOE, EPA, DOT — make awards on rolling timelines. Corporate insiders at companies positioned to receive these awards (EV manufacturers, grid infrastructure builders, utility-scale solar and wind developers, transmission equipment makers) often have visibility into their award probability before public announcement.

Key sector tickers for this lens: Grid infrastructure (AMSC, ENPH in inverter/power electronics), utility-scale solar (FSLR for domestic manufacturing content), transmission (PWR, WESCO), EV charging infrastructure (CHPT, BLNK), and the large utilities navigating rate cases tied to federal grid investment (NEE, DUK, SO). Also watch the industrial companies positioned for reshoring and manufacturing investment — ETN, EMR, ROK — where federal industrial policy drives capex cycles.

Congressional overlay: Energy Committee members and Environment and Public Works members with positions in utilities, oil and gas, or clean energy are the names to watch. The signal is clearest when a member with direct jurisdiction over energy tax credits or production incentives holds meaningful positions in companies that directly benefit from those credits.

What makes this category different: Because federal infrastructure awards are frequently announced publicly and tracked in USASpending.gov and grants.gov, it is possible to retroactively verify whether insider buying preceded a federal award. This is the most falsifiable of the insider-trade patterns, and the data is publicly available to check.

The financial sector produces a distinct category of insider-trade signal because it sits at the intersection of two powerful policy levers: Federal Reserve monetary policy and congressional banking regulation. Corporate insiders at banks and brokerages have a direct, immediate read on their own net interest margin — the spread between what they earn on loans and what they pay on deposits — which is the primary driver of bank earnings in a rate-sensitive environment.

The NIM mechanism: When rates rise, banks with large loan books and sticky deposit bases see net interest margin expand quickly. When rates fall or plateau, the dynamic reverses. Bank executives buying stock aggressively during a period of rate uncertainty signals their read on the forward NIM trajectory — and they know their own book better than any sell-side analyst.

This dynamic is clearest at regional and mid-cap banks (CFG, RF, HBAN, KEY, MTB, ZION), where the NIM effect is less diluted by fee-based businesses than at the money-center banks (JPM, BAC, WFC, GS, MS).

Congressional angle: Senate Banking Committee and House Financial Services Committee members with financial-sector holdings are the obvious watch list. The policy levers they oversee — capital requirements, merger approval processes, CFPB rulemaking authority — have direct valuation implications for financial-sector companies. Cluster buying in financial stocks by these members ahead of regulatory announcements is the pattern to flag.

The inverse signal — what selling tells you: Heavy selling by bank executives in the period before a regional banking stress event (rising commercial real estate delinquencies, deposit outflow concerns) is often the most legible signal in the disclosure system. The 2023 regional banking episode produced precisely this pattern at several institutions. Executives with the best view of their own loan portfolios and deposit stability were reducing exposure before the market fully priced the risk.

Noise to filter: Bank executives routinely sell shares for tax planning and option-exercise reasons. The signal-to-noise ratio improves significantly when you focus on open-market purchases — executives spending their own cash, not just exercising and selling grants.

The Insider Trade will track a small number of notable filings each week against a simple scoring rubric. We are not making trade recommendations. We are building a public record of what insiders signaled, what the subsequent policy or corporate development was, and whether the signal proved informative.

Signal Strength (1–5):

• 5: Open-market purchase, no 10b5-1 plan, multiple insiders at same company or same sector, immediately preceding a known policy window or catalyst event.
• 4: Open-market purchase, single insider, in a sector with a clearly upcoming policy catalyst.
• 3: Open-market purchase with some ambiguity about motivation (part of a broader portfolio rebalancing, unclear relationship to policy).
• 2: Option exercise and hold, or small discretionary purchase with no clear policy link.
• 1: 10b5-1 plan execution, estate-related sale, or index rebalancing with no directional information content.

Outcome Tracking: We will revisit notable signals six to twelve weeks after the filing and note what, if anything, was announced. The goal is to build an empirical record of which types of insider transactions have historically preceded meaningful corporate or policy developments — and which are simply noise that the disclosure system captures but that carries no forward-looking information.

One standing caveat: This column deals in probabilities, not certainties. An insider buying stock before a favorable development is not evidence of illegality. Most of these trades are fully legal, and many are coincidental. What we are looking for is the base rate — whether certain types of insider activity, in certain sector contexts, around certain policy windows, correlate with subsequent developments at rates above random. That is the intelligence we are building.

Next week, we will dig into specific recent filings across these categories and begin applying the framework to live data.